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IMPORTANCE Surgical resection has a potential benefit for patients with metastatic
adenocarcinoma of the stomach and gastroesophageal junction.
OBJECTIVE To evaluate outcome in patients with limitedmetastatic disease who receive
chemotherapy first and proceed to surgical resection.
DESIGN, SETTING, AND PARTICIPANTS The AIO-FLOT3 (Arbeitsgemeinschaft Internistische
Onkologie–fluorouracil, leucovorin, oxaliplatin, and docetaxel) trial is a prospective, phase 2
trial of 252 patients with resectable or metastatic gastric or gastroesophageal junction
adenocarcinoma. Patients were enrolled from 52 cancer care centers in Germany between
February 1, 2009, and January 31, 2010, and stratified to 1 of 3 groups: resectable (arm A),
limitedmetastatic (arm B), or extensive metastatic (arm C). Data cutoff was January 2012,
and the analysis was performed in March 2013.
INTERVENTIONS Patients in armA received 4 preoperative cycles of fluorouracil, leucovorin,
oxaliplatin, and docetaxel (FLOT) followed by surgery and 4 postoperative cycles. Patients in
armB received at least 4 cycles of neoadjuvant FLOT and proceeded to surgical resection if
restaging (using computed tomography andmagnetic resonance imaging) showed a chance of
margin-free (R0) resection of the primary tumor and at least amacroscopic complete resection
of themetastatic lesions. Patients in armCwere offered FLOT chemotherapy and surgery only if
required for palliation. Patients received amedian (range) of 8 (1-15) cycles of FLOT.
MAIN OUTCOMES ANDMEASURES The primary end point was overall survival.
RESULTS In total, 238 of 252 patients (94.4%) were eligible to participate. Themedian
(range) age of participants was 66 (36-79) years in arm A (n = 51), 63 (28-79) years in arm B
(n = 60), and 65 (23-83) years in arm C (n = 127). Patients in arm B (n = 60) had only
retroperitoneal lymph node involvement (27 patients [45%]), liver involvement (11 [18.3%]),
lung involvement (10 [16.7%]), localized peritoneal involvement (4 [6.7%]), or other (8
[13.3%]) incurable sites. Median overall survival was 22.9months (95% CI, 16.5 to upper level
not achieved) for arm B, compared with 10.7 months (95% CI, 9.1-12.8) for arm C (hazard
ratio, 0.37; 95% CI, 0.25-0.55) (P < .001). The response rate for arm Bwas 60% (complete,
10%; partial, 50%), which is higher than the 43.3% for arm C. In arm B, 36 of 60 patients
(60%) proceeded to surgery. Themedian overall survival was 31.3 months (95% CI,
18.9-upper level not achieved) for patients who proceeded to surgery and 15.9months (95%
CI, 7.1-22.9) for the other patients.
CONCLUSIONS AND RELEVANCE Patients with limitedmetastatic disease who received
neoadjuvant chemotherapy and proceeded to surgery showed a favorable survival. The
AIO-FLOT3 trial provides a rationale for further randomized clinical trials.
TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00849615
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G astric cancer is often diagnosed in locally advanced ormetastatic stage and, therefore, has a poor prognosis.Systemic chemotherapy is recommended for patients
withstage IIor IIIdiseaseasneoadjuvantorperioperative treat-
ment and for patients with stage IV as a single-modality treat-
ment. In the latter case, only 10% of the patients survive lon-
ger than2years.Unlikewithother tumorentities, suchascolon
and ovarian cancer, in which multimodality approaches are
frequently used for select patients in stage IV, patients with
metastatic gastric cancer generally receive only palliative
chemotherapy.
A number of retrospective analyses examined the role of
surgery of the primary tumor and/or metastases for patients
with stage IV gastric cancer and suggested that surgerymight
be associatedwith prolonged survival in select patients, such
as those 70 years or youngerwho had 1metastatic site,1 those
with 1 incurable site and excellent response to systemic pre-
operative chemotherapy,2,3 and thosewith livermetastases in
whomcomplete resectionwaspossible.4However, the role of
surgical intervention formetastatic gastric cancer remains an
open question. A recent trial in Asia (REGATTA) randomized
175 patients with gastric cancer and a single noncurable site
to chemotherapy alone or to initial gastrectomy (without re-
sectionof themetastases) followedbychemotherapy.That trial
failed to show improvements in survival.5
In thedebateonhowtoconduct furtherstudies in this field,
weconsider3 theoretical aspects tobe important: (1) theproper
selection of suitable candidates for surgery, (2) the clear defi-
nitionof the goal of the surgery (eg, palliative or curative), and
(3) the necessity to administer effective systemic chemo-
therapy prior to surgery.
Here, we report on the feasibility and efficacy of using
inductionchemotherapywith fluorouracil, leucovorin,oxalipl-
atin, anddocetaxel (FLOT) followedby surgical resectionwith
curative or life-prolonging intent for select patients with lim-
itedmetastaticgastriccancer.WechoseFLOTtreatmentbecause
of its confirmed tolerability6,7 and ability to induce consider-
able rates (up to20%)of completepathological regression.8-10
Methods
Patient Eligibility
Patientswith histologically confirmed, previously untreated,
nonmetastatic, operable (>T2,Nany, andM0or anyT,N+, and
M0) or metastatic (T any, N any, and M1) adenocarcinoma of
the stomach or esophagogastric junctionwere eligible to par-
ticipate in this AIO–FLOT3 (Arbeitsgemeinschaft Internis-
tische Onkologie–fluorouracil, leucovorin, oxaliplatin, and
docetaxel) trial (NCT00849615).Patientswithrecurrentdisease
werenot.AnEasternCooperativeOncologyGroupperformance
status of 0 to 2, sufficient bonemarrow and kidney function,
andnoconcurrent,uncontrolledmedical illnesswere required
of trial participants. The protocol (available in Supplement 1)
and the patient informed consent formwere approved by the
ethics committees of all participating cancer care centers
(eAppendix 1 in Supplement 2). Participants providedwritten
informed consent.
Clinical Staging and Group Stratification
Patients underwent preoperative staging that consisted of
endoscopy, endoscopic ultrasonography, and computed to-
mography (CT) or magnetic resonance imaging (MRI) of the
chest, abdomen, andpelvis. Patientswhowerepotentially re-
sectable or had limited metastases were recommended to
undergodiagnostic laparoscopy. In case of suspectedbone le-
sions on CT scans, additional bone scans were required.
After pretreatment staging, patients were stratified by
the investigator into 1 of 3 groups—resectable (armA), limited
metastatic (armB), or extensivemetastatic (armC)—using the
following criteria:
• ArmA, resectable tumorswithout distantmetastases (cM0).
• Arm B, metastatic tumors (cM1) with all of the following
criteria fulfilled:
• abdominal, retroperitoneal lymphnodemetastasesonly (eg,
para-aortic, intra-aortic-caval, peripancreatic, ormesente-
rial lymph nodes) or 1 incurable organ site with or without
retroperitoneal lymph node metastases;
• no clinically visible (on CT scans or because of ascites) or
symptomatic carcinomatosis of peritoneum or pleura and
no diffuse (>P2 score; eAppendix 2 in Supplement 2) peri-
toneal carcinomatosis on diagnostic laparoscopy;
• fewer than 5 liver metastases, if the single organ site is the
liver;
• EasternCooperativeOncologyGroupperformance statusof
0 or 1; and
• normal serum alkaline phosphatase levels.
• Furthermore, the following specific caseswere predefined
in the study protocol: localized peritoneal carcinomatosis
(P1 or P2 score), according to the classification of the Japa-
nese Research Society for Gastric Cancer, was allowed and
considered 1 incurable organ site. Bilateral or unilateral
Krukenberg tumors were allowed and considered 1 incur-
able organ site. Unilateral or bilateral adrenal glandmetas-
tases were also considered 1 incurable organ site. Extra-
abdominal lymphnodemetastases, suchas supraclavicular
lymph node involvement, were allowed and considered 1
incurable organ site.
• Arm C, metastatic patients who did not fulfill the criteria of
arm B.
Key Points
Question Is there a survival benefit for patients with limited
metastatic gastric or gastroesophageal junction cancer who
receive neoadjuvant chemotherapy followed by surgical resection?
Findings In this phase 2 trial that enrolled 252 patients with
resectable or metastatic gastric or gastroesophageal junction
adenocarcinoma, 60 of the 238 eligible patients were classified as
having limitedmetastatic stage and 36 of these 60 patients had
surgery, including resection of the primary tumor andmetastases.
Themedian overall survival was 31.3 months for patients who
underwent surgery and 15.9months for the other patients.
Meaning Patients with limitedmetastatic gastric or
gastroesophageal junction cancer may benefit from neoadjuvant
chemotherapy followed by surgical resection.
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Retroperitoneal lymphnode involvementwasdefinedas an
abnormally increasednumberof retroperitoneal lymphnodes
measuringmore than1cmin theshort-axisdiameterora single
lymph node measuring more than 2 cm in the short-axis
diameter. The stratification was confirmed by central review
(S.-E.A.-B.). If necessary, central review requested additional
information and documents or contacted the investigator to
achieve consensus.
Treatment Plan
The FLOT chemotherapy consisted of oxaliplatin, 85
mg/m2; leucovorin, 200 mg/m2; and docetaxel, 50 mg/m2.
Each is an intravenous infusion followed by fluorouracil,
2600 mg/m2, as a 24-hour continuous intravenous infusion
on day 1, repeated every 2 weeks.6 (FLOT is a 2-week
regimen.)
Patients in arm A received 4 cycles of preoperative FLOT
followed by surgery and 4 postoperative cycles. Patients in
arm B received 4 cycles of FLOT and proceeded to surgery if
restaging showed a realistic chance for margin-free (R0)
resection of the primary tumor and at least a “macroscopic
complete resection” of the metastatic lesions. For final de-
cision, we took into consideration the current patient’s
Eastern Cooperative Oncology Group performance status,
comorbidity, organ function, and response to FLOT treat-
ment. After surgery, patients in arm B received 4 additional
postoperative cycles of FLOT (8 cycles in total). Patients
who did not proceed to surgery after the fourth cycle con-
tinued to receive 4 additional cycles (8 cycles in total).
Patients in arm C received 8 cycles, and surgical interven-
tions were allowed for palliative reasons. In treatment arms
B and C, the maximum duration of FLOT treatment could be
extended to a maximum of 12 cycles at the investigator’s
discretion.
Surgery
Restaging through CT orMRI scans and endoscopy of the up-
per gastrointestinal tract was repeated after 4 cycles prior to
surgical treatment, which was 3 weeks after the last cycle of
preoperative chemotherapy. Surgery was performed accord-
ing to German standards: the AIO-FLOT3 trial protocol sug-
gested transthoracic esophagectomy with resection of the
proximal stomach (Ivor-Lewis procedure) and 2-field lymph-
adenectomy for type I gastroesophageal junction cancers and
gastrectomy with transhiatal distal esophagectomy plus D2
lymphadenectomy for types II and III gastroesophageal junc-
tion cancers. For gastric cancer, total or subtotal distal gas-
trectomywithD2 lymphadenectomywas recommended. The
study protocol provided recommendations on surgical inter-
vention for these specific situations in arm B: para-aortic in-
volvement, peripheral or central liver metastases, localized
peritoneal carcinomatosis, and metastases to adrenal glands
(eAppendix 2 in Supplement 2).
Toxicity Assessment
Toxic effectswere gradedaccording to theNational Cancer In-
stitute’s Common Toxicity Criteria, version 3.0.11 Postopera-
tive morbidity andmortality were recorded.
Evaluation of Efficacy Outcomes
Response in the metastatic groups (arms B and C) was classi-
fiedaccording toRECIST (ResponseEvaluationCriteria inSolid
Tumors), version 1.0.12 Tumor assessment throughCTorMRI
scans was carried out every 8weeks during and after the end
of thestudytreatment (forpatientswhodiscontinuedthestudy
without disease progression). R0 resectionwas defined as no
tumor identifiedonmicroscopic examinationofproximal, dis-
tal, or circumferential margins.
End Points and Statistical Analysis
Weassumed that if patients in armB (independent ofwhether
patients had an operation) showed a better outcome than did
patients in arm C, we could justify the further evaluation of
neoadjuvant chemotherapy followed by surgical resection in
the patient group of arm B. Therefore, the primary end point
was overall survival (OS), and the study had 80% power to
detect a 45% risk reduction of death in arm B compared
with arm C (hazard ratio [HR], 0.55), with P < .05 in the
2-tailed log-rank test indicating statistical significance.
Assuming that approximately 30% of metastatic patients in
the study group would match the criteria for arm B (did not
reflect the natural prevalence of this group), we calculated
the sample size to be 192 (arm B, 64; arm C, 128). Arm A did
not have an effect on sample size calculation and was
capped at 50 patients. Progression-free survival was mea-
sured from the date of arm assignment until disease pro-
gression or death of any cause. Similarly, OS was measured
from the date of arm assignment until death of any cause.
Data cutoff was January 2012, and the analysis was per-
formed in March 2013. Patients were analyzed in the arm to
which they were assigned.
Results
Patient Characteristics
BetweenFebruary 1, 2009, and January 31, 2010,we enrolled
252 patients (and stratified them to arm A, 52; arm B, 67; and
arm C, 133) in 52 centers in Germany (eAppendix 1 in
Supplement 2). Of the 252 patients, 14 (5.6%) were excluded
from the efficacy analysis for these reasons: 10 had recurrent
disease, 2 had ineligible underlying disease (ie, breast cancer,
hepatocellular carcinoma), 1 had received prior chemo-
therapy, and 1was stratified intoarmBbutwas confirmedhav-
ingM0disease at on-sitemonitoring. Therefore, 238 patients
(94.4%) were eligible for the efficacy analysis (arm A, 51 pa-
tients; arm B, 60; arm C, 127). Details are shown in Figure 1.
The median (range) age of participants was 66 (36-79) years
inarmA,was63 (28-79)years inarmB,andwas65 (23-83)years
in armC. Themajority of patients had anEasternCooperative
OncologyGroupperformancestatusof0or 1. Pretreatmentpa-
tient characteristics are shown ineTable 1 inSupplement2. Pa-
tients in arm B were more likely to have their primary tumor
in the gastroesophageal junction. All other differences be-
tween the 3 arms were attributable to trial protocol defini-
tions. The largest subgroup of armB comprised patients with
only retroperitoneal lymph node metastases, accounting for
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27 of 60 patients (45%), followed by patients with liver me-
tastases (11 [18.3%]).
Chemotherapy and Surgical Treatment
Patients receivedamedian(range)of8 (1-15)cyclesofFLOT.The
median (range) numbers of preoperative and postoperative
cycles were 4 (preoperative, 3-15; postoperative, 1-7) for each
armsofAandB.Forty-ninepatients (96.1%) inarmA,36 (60%)
in arm B, and 15 (11.8%) in arm C proceeded to any surgical re-
section. R0 resections of the primary tumor were achieved in
40patients (81.6%) inarmA,29 (80.6%) inarmB,and5 (33.3%)
in armC.As shown ineTable 2 inSupplement2, fewerpatients
in arm B than in arm A had a right transthoracic esophagec-
tomy with 2-field lymph node dissection despite the fact that
junctional tumors weremore frequent in arm B.
InarmB,surgerywasperformedin18of27patients (66.7%)
with retroperitoneal lymph node metastases, 6 of 11 (54.5%)
with liver metastases, 6 of 10 (60%) with lung metastases, 2
of 4 (50%) with local peritoneal carcinomatosis, and 4 of 8
(50%) with other metastases. Metastasectomy of at least 1
metastatic lesionwasperformed in17of the36patients (47.2%)
whowere assigned to surgery in arm B. These surgical proce-
dures includedD3 lymphadenectomy in7patients, peritonec-
tomy in 3,multivisceral resections in 3, hepatectomy in 3, and
adrenalectomy in 1. Among the 18 patients with retroperito-
neal lymphnodemetastaseswhounderwenta resection,meta-
static lymph node involvement could be confirmed in 11 pa-
tients but was not assessable in 3 patients who had complete
pathological regressionandcouldnotbeconfirmed in theother
4patients. Completepathological regression (stageofT0)was
reported in 6 of 36 patients (16.7%) of arm B who underwent
resection. Complete regression in resected metastatic le-
sions, as indicated by fibrotic changes and the absence ofma-
lignant cells,was noticed in 3 patients (retroperitoneal lymph
nodes in 2 patients and liver lesions in 1 patient). The reasons
for not assigning patients to surgery in arm B were unresect-
ableor incurablemetastatic lesions in 11of60patients (18.3%),
inadequate response in 6 (10%), death in 2 (3.3%), complete
response in 1 (1.7%), medical inoperability in 1 (1.7%), patient
refusal in 1 (1.7%), andunknown in2 (3.3%), as reportedby the
investigator.
Efficacy Outcomes
Median follow-up for survivingpatientswas28.6months (arm
A, 30.3months; armB, 27.5months; armC, 24.4months).Me-
dian OS was 22.9 (95% CI, 16.5-upper level not achieved)
months in arm B and 10.7 (95% CI, 9.1-12.8) months in arm C
(HR, 0.37; 95% CI, 0.25-0.55; P < .001). Median OS in arm A
was not achieved and compared favorably with the median
OS in arm B. The analysis of progression-free survival among
the arms revealed distributions similar to OS distributions
(Figure 2).
Figure 1. CONSORTDiagram
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owing to underlying
disease)
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limited metastatic
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analysis
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safety analysis
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Within arm B, patients who proceeded to surgery had
more favorable median OS (31.3 months [95% CI, 18.9-upper
level not achieved] vs 15.9 months [95% CI, 7.1-22.9]) and
progression-free survival (26.7 months [95% CI, 9.1-upper
level not achieved] vs 8.4 months [95% CI, 4.1-10.4]) than
the other patients in arm B (Figure 2). Outcomes with 95%
CIs are shown in Table 1. Among the subgroups of arm B,
only patients with retroperitoneal lymph node metastases
had the best prognosis, whereas patients with liver metasta-
ses showed a less favorable survival (eFigure in Supplement
2). The overall response rate (complete and partial response)
to chemotherapy was higher in arm B patients than in arm C
patients (60.0% vs 43.3%; P = .04). Response rates are
shown in Table 2.
We compared the baseline characteristics and comorbidi-
ties of patients who proceeded to surgerywith thosewho did
not within arm B. No differences in age, sex, location of the
primary tumor,histological type, typeofmetastases, andother
characteristicswere found.However, patientswhodidnotun-
dergosurgeryhadsignificantlymoreactivecomorbidities than
patientswhohadsurgery (20of24 [83.3%]vs 18of 36 [50.0%];
P = .009), particularly of the cardiovascular type (15 of 24
[62.5%] vs 10 of 36 [27.8%]; P = .008), and less complete re-
sponses (1 of 24 [4.2%] vs 5 of 36 [13.9%]; Table 2) during
chemotherapy.
Safety
The safety analysis comprised all 252 patients. The safety
profile of FLOT was in line with the profile of previous
studies.6,7,10,13 Patients in arm C had significantly more Com-
mon Toxicity Criteria all-grades anemia, pain, and elevated
alkaline phosphatase levels, most likely correlated with the
high tumor burden (eTable 3 in Supplement 2). Severe post-
surgical morbidity (fulfilling the criteria of a serious adverse
event) affected 5 patients (10.2%) in arm A and 3 patients
(8.3%) in arm B (eTable 4 in Supplement 2). Numbers do not
Figure 2. Survival Analyses
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survival (D) in patients with limitedmetastatic disease (arm B) who underwent
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represent the overall postsurgical morbidity because only
those that resulted in serious adverse events are reported.
In-hospital mortality after surgery occurred in 1 patient in
arm A.
Discussion
The AIO-FLOT3 trial was an exploratory, phase 2 study that
prospectively evaluated the feasibility and efficacy of
induction chemotherapy followed by surgery for patients
with limited metastatic gastric cancer who had additional
favorable prognostic factors. Sixty patients had limited
metastatic disease (arm B), and they had a considerable
median OS of 22.9 months. Of the 60 patients, 36 (60%)
proceeded to surgery. The median OS was 31.3 months for
patients who underwent surgery and 15.9 months for the
other patients. Both groups had survival rates that were
markedly better than the expected survival for metastatic
disease, which were generally accepted to be 9 to 11 months
in recent trials. The important question is to what extent
surgery contributed to the favorable outcome of the
resected group. Because of the lack of randomization, rel-
evant selection bias may exist. For instance, a difference in
comorbidity was observed between the groups. Patients
assigned to surgery had less active comorbidity than the
patients who did not have surgery (50.0% vs 83.3%). The
most common reason for not assigning patients to surgery
was the investigator’s decision that metastatic lesions were
unresectable or incurable after neoadjuvant chemotherapy.
Conversely, this means that patients assigned to surgery
were superselected. Nevertheless, within these limitations,
the considerable survival in the surgical group of arm B
remains promising. A median survival of 31 months is more
than we would expect in a superselected group of patients
with metastatic disease.
Patients with retroperitoneal lymph node metastases or
livermetastases represented the2 largest subgroupsof armB.
Patientswith retroperitoneal lymphnodemetastases showed
the best survival. This patient groupmaybe of a particular in-
terest for suchabimodality therapyapproach.14-18One impor-
tant point is whether CT or MRI was sufficient to determine
retroperitoneal involvement.TheaccuracyofCTorMRI forde-
fining lymphnode involvement is dependent on the anatomi-
cal location. In the abdomen, theupper limit of the short-axis
diameter ofnormalnodesvaries from6 to 10 mm.19The study
protocol went beyond these definitions, requiring either too
many lymph nodes (lymph node clusters) greater than 1 cm
in the short axis or single lymph nodes greater than 2 cm.
Therefore, we do not believe that arm B was inflated by pa-
tientswith nonmetastatic lymphatic hyperplasia. The less fa-
vorable outcome of patients with livermetastases leads us to
recommend toeither exclude this group in future trials or limit
the group to patients in whom complete (R0) resection is
judged possible at initial evaluation. Nevertheless, few pa-
tientswithmetastatic gastric cancerwill have initially resect-
able liver disease.4,20
The REGATTA trial5 randomized 175 patientswith gastric
cancer and a single noncurable site confined to liver, perito-
neum, or para-aortic lymph nodes to chemotherapy alone or
gastrectomy followed by chemotherapy. The study did not
showany improvementofOSbygastrectomy (medianOS, 16.6
months without gastrectomy and 14.3 months with
gastrectomy).5 The concept of theREGATTA trial differs from
the concept of theAIO-FLOT3 trial in 2 importantways. First,
patients in the REGATTA trial did not receive neoadjuvant
chemotherapy. Second, the surgical intervention was re-
stricted to only gastrectomywithD1 lymphadenectomywith-
out any resection of metastatic lesions, making the study
palliative rather than curative. Asmentioned in the Introduc-
Table 1. Median Overall Survival and Progression-Free Survival by Arm
Study Arm
Survival
Median OS (95% CI), mo Median PFS (95% CI), mo
Arm A NA NA
Arm B
All 22.9 (16.5-NA) 10.7 (8.0-16.5)
With surgery 31.3 (18.9-NA) 26.7 (9.1-NA)
Without surgery 15.9 (7.1-22.9) 8.4 (4.1-10.4)
Arm C 10.7 (9.1-12.8) 6.3 (5.0-7.6)
Abbreviations: NA, not achieved; OS, overall survival; PFS, progression-free
survival.
Table 2. Response Rates According to RECIST for PatientsWith Limited (ArmB) and Extensive (Arm C)Metastatic Disease
Study Arm
Best Responsea
Complete Response, No.
(%) [95% CI]
Partial Response, No. (%)
[95% CI]
Overall Response,
Complete + Partial, No. (%)
[95% CI]b
Stable Disease, No.
(%) [95% CI]
Progressive Disease/
Not Evaluable, No. (%)
[95% CI]
Arm B
All (n = 60) 6 (10.0) [4.3-20.5] 30 (50.0) [37.7-62.3] 36 (60.0) [47.4-71.4] 18 (30.0) [19.8-42.6] 5 (8.3) [3.2-18.5]
With surgery
(n = 36)
5 (13.9) [5.6-29.1] 15 (41.7) [27.1-57.8] 20 (55.6) [39.6-70.5] 14 (38.9) [24.8-55.2] 1 (2.8) [<0.01-15.4]
Without surgery
(n = 24)
1 (4.2) [<0.01-21.9] 15 (62.5) [42.6-78.9] 16 (66.7) [46.6-82.2] 4 (16.7) [6.1-36.5] 4 (16.7) [6.1-36.5]
Arm C (n = 127) 5 (3.9) [1.5-9.1] 50 (39.4) [31.3-48.1] 55 (43.3) [35-52] 44 (34.6) [26.9-43.3] 23 (18.1) [12.3-25.8]
a Best response refers to the best response achieved as evaluated by
comparison of baseline tumor assessment with all available, subsequent
tumor assessments until surgical resection was conducted, if applicable.
Tumor assessments performed after surgery were not relevant for response.
bP = .04 for the numbers of patients with overall response (complete + partial)
in arm B compared with those in arm C, using 2-sided Fisher exact test. The P
value is presented only if P < .05.
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tion, we believe the use of neoadjuvant therapy and the pur-
suit of a potentially curative surgery are 2 crucial factors in a
multimodality approach to a biologically aggressive disease
such as metastatic gastric cancer. Administering chemo-
therapy firsthelpsprevent adelay inadministrationof the sys-
temic treatment component, which has been proven to be ef-
fective.Moreover, administering chemotherapy first provides
a tool for selectingpatientswith thehighest likelihood toben-
efit from additional surgery, on the basis of their response to
treatment and other factors.
Limitations
Themain limitationof theAIO-FLOT3 trialwas the lackof ran-
domization. Another limitation was the use of CT or MRI to
determine retroperitoneal involvement. Both of these topics
were addressed in the discussion.
Conclusions
To our knowledge, the AIO-FLOT3 trial is the first prospec-
tive study toevaluateneoadjuvant chemotherapy followedby
surgery in patients withmetastatic gastric and gastroesopha-
geal junction cancer. Within the limitations of a nonrandom-
ized phase 2 study, the results reported here showed that the
conceptwas feasible and provided a rationale for an ongoing,
randomized, phase 3 trial21 funded by the German Research
Foundation Deutsche Forschungsgemeinschaft.
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